James A Posey III MD
Gastrointestinal Cancer, Hematologic Oncology
Professor, Director of GI Program Dept of Oncology Co-Leader GI Program SKCC
Join to View Full Profile
1025 Walnut StreetSuite 700Philadelphia, PA 19107
Phone+1 215-503-6442
Dr. Posey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
MedStart Georgetown University HospitalFellowship, Medical Oncology, 1994 - 1996
MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 1991 - 1994
Howard University College of MedicineClass of 1991
Certifications & Licensure
MD State Medical License 2024 - 2027
PA State Medical License 2016 - 2024
NJ State Medical License 2017 - 2023
DE State Medical License 2017 - 2021
AL State Medical License 1997 - 2016
DC State Medical License 1995 - 1998
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification HealthSentry, Cerner Corporation, 2012, 2014, 2016
- CMS Meaningful Use Stage 2 Certification Cerner Patient Portal and Powerchart, Cerner Corporation, 2012, 2014, 2016
- CMS Meaningful Use Stage 2 Certification PowerChart (Clinical), Cerner Corporation, 2012, 2014, 2016
Clinical Trials
- ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas Start of enrollment: 2000 Jul 01
- Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer Start of enrollment: 2002 Jan 01
- Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors Start of enrollment: 2007 Aug 01
Publications & Presentations
PubMed
- 1 citationsEarly outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma.Spencer J Poiset, Sophia Shah, Louis Cappelli, Pramila Anné, Karen E Mooney
Radiation Oncology. 2024-05-29 - 7 citationsPhase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.Oluwadunni E Emiloju, Jun Yin, Emily Koubek, Joel M Reid, Mitesh J Borad
Investigational New Drugs. 2024-02-01 - 16 citationsFeasibility of a Text Messaging-Integrated and Chatbot-Interfaced Self-Management Program for Symptom Control in Patients With Gastrointestinal Cancer Undergoing Chemo...Sameh Gomaa, James Posey, Babar Bashir, Atrayee Basu Mallick, Eleanor Vanderklok
JMIR Formative Research. 2023-11-10
Press Mentions
‘I Had 18 Months to Live, I’m Still Fighting Colon Cancer’April 12th, 2023
Grant Support
- UAB 0282 GemcitabineNational Center For Research Resources2006
- Rebeccamycin In Hepatabiliary CancersNational Center For Research Resources2004
- Mentored Patient Oriented Research Career Development AwNational Center For Research Resources2000–2004
- Taxotere W/ Continuous Infusion Topotecan In Advanced MalignanciesNational Center For Research Resources1999–2002
- PNU 214936 In Advanced Adenocarcinomas Of The BreastNational Center For Research Resources1999–2002
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
